| # | Drug | Count |
|---|---|---|
| 0 | PEMBROLIZUMAB | 11 |
| 1 | NIVOLUMAB | 8 |
| 2 | IPILIMUMAB | 7 |
| 3 | CISPLATIN | 3 |
| 4 | INFLIXIMAB | 3 |
| 5 | LENVATINIB | 3 |
| 6 | VONOPRAZAN FUMARATE | 3 |
| 7 | ACETAMINOPHEN | 2 |
| 8 | ACETAMINOPHEN 500MG | 2 |
| 9 | ACETAMINOPHEN TABLET EXTENDED RELEASE | 2 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | OBECABTAGENE AUTOLEUCEL | 1 | 0.0141 |
| 1 | VONOPRAZAN FUMARATE | 3 | 0.0004 |
| 2 | HYDROCORTISONE SODIUM SUCCINATE | 1 | 0.0003 |
| 3 | PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF | 1 | 0.0002 |
| 4 | IPILIMUMAB | 7 | 0.0002 |
| 5 | CILTACABTAGENE AUTOLEUCEL | 1 | 0.0002 |
| 6 | PEMBROLIZUMAB | 11 | 0.0001 |
| 7 | LENVATINIB | 3 | 0.0001 |
| 8 | VEMURAFENIB | 1 | 0.0001 |
| 9 | NIVOLUMAB | 8 | 0.0001 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Interleukin-5 Antagonist [EPC] | 1 | 0.0015 |
| 1 | Endoglycosidase [EPC] | 1 | 0.0005 |
| 2 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 18 | 0.0002 |
| 3 | CTLA-4-directed Blocking Antibody [EPC] | 7 | 0.0001 |
| 4 | Bile Acid [EPC] | 1 | 0.0000 |
| 5 | Platinum-based Drug [EPC] | 4 | 0.0000 |
| 6 | HER2/neu Receptor Antagonist [EPC] | 1 | 0.0000 |
| 7 | Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor [EPC] | 1 | 0.0000 |
| 8 | Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC] | 1 | 0.0000 |
| 9 | Histamine-2 Receptor Antagonist [EPC] | 1 | 0.0000 |